IgA Nephropathy Market By Therapy Type (Corticosteroid-Sparing Therapies, Endothelin Receptor Antagonists, Complement Inhibitors, Supportive Care); By Route of Administration (Oral, Injectable); By End User (Academic and Tertiary Hospitals, Specialty Nephrology Clinics, Retail and Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

IgA Nephropathy Market: Kidney-Function Evidence and Immune-Targeted Therapies Reshape Commercial Competition

The Global IgA Nephropathy Market is set to register strong expansion at a CAGR of 18.28%, growing from USD 135.61 million in 2025 to USD 439.21 million by 2032, according to Strategic Market Research.

 

The IgA nephropathy market is moving from a supportive-care category into a multi-mechanism specialty-pharmaceutical market. IgA nephropathy, also called Berger’s disease, develops when abnormal immunoglobulin A-containing immune complexes accumulate in the kidney’s filtering units and cause inflammation, protein leakage, scarring, and gradual loss of kidney function. Treatment historically depended on blood-pressure control, renin-angiotensin system blockade, dietary sodium reduction, and systemic corticosteroids. The market now includes targeted-release budesonide, dual endothelin and angiotensin receptor antagonism, selective endothelin-A blockade, complement inhibition, APRIL inhibition, and combined BAFF-APRIL inhibition.

 

A publicly disclosed U.S. addressable-market assessment places the potential IgA nephropathy treatment opportunity at approximately USD 20 billion. The calculation is based on about 169,000 U.S. patients, of whom an estimated 60%–75% have persistent proteinuria and could qualify for newer disease-modifying therapies. This figure represents potential annual treatment opportunity rather than current realized pharmaceutical revenue.

 

The commercial change is visible in product uptake. Filspari generated USD 322 million in U.S. net product sales during 2025, 144% above 2024, when sales were approximately USD 132 million. Fourth-quarter 2025 sales reached USD 103.3 million, and the company received 908 new patient-start forms. First-quarter 2026 sales increased another 88% year over year to USD 105.2 million, supported by a record 993 patient-start forms. These figures show that a biopsy-confirmed rare kidney disease can support substantial recurring revenue when a medicine gains nephrologist familiarity, payer coverage, and kidney-function evidence.

 

Underdiagnosis Keeps the Clinical Population Larger Than the Treated Market

IgA nephropathy is regarded as the most common primary glomerular disease worldwide, with an estimated global incidence of at least 2.5 cases per 100,000 people annually. U.S. estimates range from about 1.4 to 2.2 cases per 100,000. Published prevalence estimates vary with the data year and methodology: approximately 112,000 U.S. patients were estimated in earlier studies, while recent epidemiology sources place the diagnosed population near 160,000–200,000.

Vertex increased its estimated IgA nephropathy population across the United States and Europe from approximately 300,000 to 330,000 in 2026. The company also estimates that the global diagnosed population exceeds 1.5 million. These figures indicate that the commercial opportunity is no longer confined to a very small orphan population, although the number currently receiving branded disease-modifying treatment remains considerably lower.

Biopsy practices explain much of the geographical variation. IgA nephropathy appears in about 10% of U.S. kidney biopsies performed for glomerular disease, approximately 20% of comparable biopsies in Europe, and up to 40% across parts of East Asia. Japan and Singapore identify more cases partly because school and workplace urine-screening programs detect microscopic blood and protein before symptoms become obvious. Japan’s reported incidence is about 4.2 per 100,000, broadly consistent with published ranges of approximately 3.9–4.5 per 100,000.

U.S. incidence also differs by ancestry. A racially diverse biopsy-based study involving 9,392 biopsied individuals identified 606 adults with primary IgA nephropathy. Incidence reached 4.5 cases per 100,000 person-years among Asian and Pacific Islander adults, compared with 1.7 among Hispanic, 1.2 among White, and 0.6 among Black adults. The disease is commonly diagnosed from the late teens through the late 30s, although the broader higher-risk age range extends from approximately 10 to 40 years. Men are diagnosed roughly twice as often as women globally.

The actual patient pool is larger because symptoms may not appear for a decade or more. Visible hematuria can turn urine pink, tea-colored, or cola-colored during or shortly after a cold, sore throat, or respiratory infection. Microscopic hematuria may appear only during routine testing. Proteinuria can cause foamy urine, while edema, hypertension, fatigue, and flank discomfort become more relevant as kidney injury progresses. These signs increase demand for kidney testing but are not specific enough to confirm IgA nephropathy.

End-user implication: Academic and tertiary hospitals retain a central role because biopsy, pathology scoring, and complex treatment initiation are concentrated in specialist centres, while the expanding diagnosed population increases follow-up volume for specialty nephrology clinics.

 

Autoimmune Risk Explains Why Upstream Therapies Attract Investment

The disease is commonly described through a four-hit autoimmune model. Patients first produce galactose-deficient IgA1, after which the immune system forms IgG or IgA autoantibodies against it. These molecules combine into circulating immune complexes that deposit in the glomeruli, activate inflammatory pathways, and cause progressive scarring.

This model supports several treatment targets rather than one uniform drug class. Gut-directed budesonide reduces upstream abnormal IgA production, APRIL and BAFF-APRIL biologics suppress antibody-producing cells, complement inhibitors reduce inflammatory injury, and endothelin-directed medicines protect the filtering units from downstream damage.

Risk is also associated with family history, celiac disease, cirrhosis and other chronic liver conditions, inflammatory bowel disease, and mucosal infections. Respiratory infections often reveal the disease through visible hematuria rather than directly causing every case. There is no curative treatment, so commercial demand comes from repeated monitoring and therapies intended to slow progression over many years.

The growing range of mechanisms also makes combination treatment plausible, although limited head-to-head evidence and high cumulative costs will restrict early use. Companies capable of positioning therapies at different stages of the disease may capture a larger share of lifetime patient treatment expenditure than suppliers dependent on a single product.

 

Biopsy Confirmation Controls Entry into the Branded-Drug Market

Urinalysis identifies blood and protein, while serum creatinine and estimated glomerular filtration rate indicate how effectively the kidneys clear waste. A kidney biopsy remains the definitive diagnosis because it demonstrates dominant IgA deposits and the extent of tissue injury. Pathologists commonly apply the MEST-C scoring system, covering mesangial and endocapillary hypercellularity, segmental sclerosis, tubular atrophy, and crescents, to support risk assessment and predict progression.

This biopsy requirement is a commercial bottleneck. Patients with mild or silent disease may never reach a nephrologist, while low- and middle-income countries often have limited access to biopsy services, immunofluorescence pathology, and specialist review. Greater use of routine urine testing and lower referral thresholds can expand the diagnosed population, but conversion into pharmaceutical demand still depends on biopsy confirmation, measurable progression risk, reimbursement, and continued monitoring.

The long-term risk creates the economic case for earlier treatment. About one in five diagnosed patients develops kidney failure within 10 years, while broader studies and patient organisations estimate that 20%–40% progress to end-stage kidney disease. Some cohorts report progression approaching 40% within 20 years, and up to 50% of patients with persistent proteinuria may reach kidney failure within 10–20 years.

Dialysis and transplantation affect many patients during their economically productive years because the disease often begins in adolescence or early adulthood and progresses gradually. Therapies that delay kidney failure can therefore support higher reimbursement by reducing future dialysis, transplantation, hospitalisation, and cardiovascular expenditure.

Diagnostic-market implication: Predictive tools and biomarkers can support risk stratification and monitoring, but they are not yet substitutes for biopsy and should not be classified as the principal solution type within the IgA nephropathy therapeutics market.

 

Targeted Oral Medicines Hold the Current Revenue Base

Nefecon, marketed as Tarpeyo in the United States and Kinpeygo in Europe, established the first disease-specific commercial pathway. KDIGO supports a nine-month course for patients at risk of progression. Tarpeyo moved from accelerated U.S. approval in 2021 to full approval in 2023, while Kinpeygo subsequently moved from conditional to standard European authorisation.

Filspari created a second major oral category by combining endothelin-A and angiotensin-II receptor activity in one medicine. It replaces, rather than supplements, a conventional ACE inhibitor or ARB. In the Phase 3 PROTECT study, mean proteinuria reduction at 36 weeks was 49.8% with Filspari compared with 15.1% with irbesartan.

Full U.S. approval in 2024, based on evidence that it slows kidney-function decline, strengthened payer acceptance and contributed to the sales expansion recorded during 2025 and early 2026. Its USD 322 million U.S. revenue in 2025 represents the strongest disclosed commercial benchmark for the endothelin receptor antagonist segment.

Fabhalta introduced oral factor B inhibition against the alternative complement pathway. It first received accelerated approval after a 43.8% placebo-adjusted proteinuria reduction. Phase 3 results subsequently showed slower kidney-function decline, supporting movement toward traditional approval.

Vanrafia received accelerated approval in April 2025. It reduced proteinuria by approximately 36% versus placebo at 36 weeks and can be added to background RAS therapy. Unlike Filspari, it does not replace the patient’s existing RAS inhibitor.

Oral therapies benefit from established pharmacy distribution and the absence of recurring infusion visits, but monitoring requirements affect adoption. Filspari carries liver and pregnancy warnings and operates through a REMS programme. Fabhalta requires infection-risk management associated with complement inhibition.

Route-of-administration implication: Oral products held the dominant disclosed revenue position entering 2026, supported by Filspari’s USD 322 million U.S. sales and the established availability of Tarpeyo, Fabhalta, and Vanrafia.

 

Injectable Biologics Open the Next Growth Segment

Voyxact became the first approved selective APRIL inhibitor in November 2025. The Phase 3 VISIONARY interim analysis showed a 51.2% proteinuria reduction relative to placebo. Interim kidney-function data subsequently showed a mean eGFR increase of 0.7 millilitres per minute per 1.73 square metres compared with a decline of 4.8 in the placebo group.

Voyxact is administered subcutaneously every four weeks. A company filing estimated annual treatment cost at approximately USD 360,000–390,000. This price establishes a high-value recurring revenue model for the injectable segment but also increases the importance of prior authorisation, treatment-response documentation, and payer renewal criteria.

Trutakna expanded the injectable segment by inhibiting both BAFF and APRIL. Povetacicept could add another monthly competitor. In the Phase 3 RAINIER interim analysis, proteinuria fell 52.0% from baseline and 49.8% versus placebo at week 36. Galactose-deficient IgA1 declined 77.4% from baseline and 79.3% versus placebo, while hematuria resolution was considerably higher than with placebo.

Injectable-segment implication: Injectable corticosteroid-sparing therapies are positioned to record the strongest growth through 2032 because their 2025–2026 launches create new recurring biologic revenue from a previously limited commercial base.

 

Regional Access Separates Patient Opportunity from Revenue

North America leads current revenue because the United States has approvals across targeted corticosteroid, endothelin, complement, APRIL, and BAFF-APRIL pathways. Specialty-pharmacy networks, rare-disease pricing, patient-support services, and broad clinical-trial participation accelerate launches.

The U.S. market already supports at least USD 322 million in annual Filspari sales, while the estimated addressable opportunity reaches approximately USD 20 billion. North America therefore remains the leading commercial region even though East Asia has higher recorded disease incidence.

East Asia carries the largest patient opportunity but uneven revenue realisation. China approved Nefecon in 2023 and later implemented national reimbursement pricing. Japan’s screening infrastructure supports higher diagnosis, but local practice has historically included tonsillectomy combined with steroid pulses more often than Western care.

Europe is expanding after standard authorisations for Kinpeygo and Filspari, although national reimbursement decisions create different adoption speeds. The combined U.S. and European diagnosed population was estimated at approximately 330,000 in 2026, while the global diagnosed population exceeded 1.5 million.

Regional-growth implication: North America is expected to retain the largest revenue share through 2032, while Asia-Pacific is positioned for faster patient-volume expansion because of higher incidence, larger populations, screening programmes, and improving reimbursement.

 

Payers Will Separate Products by Evidence and Treatment Burden

The expansion of approved options does not eliminate the main market-access challenge: limited head-to-head evidence. Trials use different proteinuria thresholds, background medicines, eligibility criteria, treatment periods, and patient populations. Proteinuria reductions from separate studies therefore cannot be interpreted as direct product comparisons.

Full approvals supported by kidney-function preservation will generally carry more reimbursement weight than accelerated approvals based only on proteinuria. Combination therapy could increase revenue per patient but also intensify affordability pressure. A treatment plan may include an ACE inhibitor or ARB, an SGLT2 inhibitor, an endothelin-directed medicine, and an immune-targeted product.

Retail and specialty pharmacies will gain greater commercial relevance as oral and self-administered injectable products replace hospital-only administration. Academic and tertiary hospitals will continue to lead diagnosis and complex treatment initiation, while specialty nephrology clinics will manage long-term monitoring, therapy switching, and response assessment.

 

Acquisition Values Confirm Long-Term Competitive Confidence

Large transactions demonstrate that companies expect IgA nephropathy to support durable specialty revenue. Novartis acquired Chinook Therapeutics for USD 3.2 billion upfront and up to approximately USD 3.5 billion including contingent value. Vertex agreed to acquire Alpine Immune Sciences for approximately USD 4.9 billion, strengthening its position around povetacicept.

Asahi Kasei’s acquisition of Calliditas was valued near USD 1.1 billion and added Tarpeyo, European partnerships, and an established rare-renal commercial platform. These transactions concentrate clinical development and commercialisation inside companies capable of funding long confirmatory trials, multinational launches, patient-support programmes, and payer negotiations.

The next phase of competition will be decided by kidney-function preservation rather than proteinuria reduction alone. Oral therapies retain the current revenue advantage, while monthly and weekly biologics create the next growth cycle. Commercial leadership will depend on durable eGFR evidence, manageable safety requirements, reimbursement across major regions, and a credible role in combination therapy.

 

IgA Nephropathy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 135.61 Million
Revenue Forecast in 2032	USD 439.21 Million
Overall Growth Rate	CAGR of 18.28% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Therapy Type, By Route of Administration, By End User, By Geography
By Therapy Type	Corticosteroid-Sparing Therapies, Endothelin Receptor Antagonists, Complement Inhibitors, Supportive Care
By Route of Administration	Oral, Injectable
By End User	Academic and Tertiary Hospitals, Specialty Nephrology Clinics, Retail and Specialty Pharmacies
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of IgA nephropathy, increasing adoption of targeted kidney-function therapies, expansion of biopsy-confirmed diagnosis, growth of immune-modulating treatments, increasing focus on delaying kidney failure progression, and rising investment in specialty renal drug development
Customization Option	Available upon request